Home / Health / Zasocitinib Shows Superiority in Psoriasis Study
Zasocitinib Shows Superiority in Psoriasis Study
30 Sep
Summary
- Zasocitinib demonstrated superior efficacy over deucravacitinib.
- Rapid, durable skin clearance achieved with zasocitinib.
- Oral treatment showed improvements in itch and quality of life.
New data presented at the EADV Congress 2026 indicate zasocitinib, an investigational oral TYK2 inhibitor, offers superior efficacy in treating plaque psoriasis. Takeda announced results from Phase 3 LATITUDE studies, showing zasocitinib achieved significantly higher rates of complete skin clearance compared to deucravacitinib by week 16.
These pivotal study findings also demonstrate zasocitinib's capacity for rapid and durable skin clearance extending up to 52 weeks. Patients treated with zasocitinib experienced notable improvements in itch and quality of life as early as week 2.
Zasocitinib was generally well-tolerated, with no new safety signals identified. The drug is currently under review by the U.S. FDA and European Medicines Agency for moderate-to-severe plaque psoriasis treatment.
Further studies are evaluating zasocitinib for psoriatic arthritis and other inflammatory conditions, including Crohn's disease and ulcerative colitis.
